Terms ending in 2030
Every in-force patent on Anavex Life Sciences Corp.'s record whose computed term ends in 2030, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 9,180,106 | Sigma Receptors Ligands with Anti-Apoptotic And/Or Pro-Apoptotic Properties, Over Cellular Mechanisms, Exhibiting Prototypical Cytoprotective and Also Anti-Cancer Activity In force · High confidence | Anavex Life Sciences Corp. | In force | High confidence |
1 of 1 patent shown. Soonest term end first, then patent number.
Updated Nov 20, 2026 · includes USPTO assignment data published Nov 19, 2026, status data published Nov 20, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.